Business Context and Reporting Period
Company: Deckers Outdoor Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1999
Business Overview: The Company designs, markets, and distributes outdoor footwear under the Teva, Simple, and Ugg brands. Operations are highly seasonal, with Teva sales peaking in Q1/Q2, Simple in Q3, and Ugg in Q4.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Net Sales | $38,040,000 | $32,177,000 |
| Gross Profit | $17,223,000 | $13,537,000 |
| Gross Margin | 45.3% | 42.1% |
| Operating Earnings | $4,554,000 | $3,389,000 |
| Net Earnings | $2,245,000 | $1,753,000 |
| Diluted EPS | $0.26 | $0.20 |
| Cash Flow from Operations | ($10,272,000) | ($11,200,000) |
| Cash Balance (End of Period) | $4,120,000 | $2,129,000 |
| Total Debt (Current + Long-term) | $35,901,000 | $N/A (Not explicitly stated for 1998) |
| Working Capital | $44,812,000 | $N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18.2% ($5.9M) driven primarily by a 40.3% surge in Teva footwear sales ($32.9M vs $23.5M). This was due to an aggressive strategy to ship product earlier in the season.
- Product Line Performance: While Teva grew significantly, Simple product line sales declined 40.4% due to competition and decreased popularity. Ugg sales remained relatively flat ($324k vs $361k) consistent with seasonal lows.
- Profitability: Gross margin improved to 45.3% from 42.1% due to better sourcing, exiting the low-margin components business, and reduced closeout impacts. Net earnings rose 28.1%.
- Expenses: Selling, general, and administrative (SG&A) expenses increased 24.8%, partly due to nearly $1.0M in special charges related to legal fees (Montana lawsuit) and corporate restructuring severance.
- Liquidity: Cash used in operating activities was $10.3M, primarily due to a $18.3M increase in trade accounts receivable and inventory buildup for the spring season. However, cash on hand increased to $4.1M due to $14.5M in net proceeds from long-term debt financing.
Guidance, Outlook, and Risks
- Outlook: Management expects full-year 1999 Teva sales to exceed 1998 levels but at a significantly lower growth rate than Q1 due to the early shipment strategy shifting revenue from Q2 to Q1. Simple sales are expected to decrease, while Ugg sales are expected to increase.
- Legal Contingencies: A $1.785M judgment was entered against the Company in May 1999 regarding a 1995 breach of non-disclosure contract. The Company is appealing and does not anticipate a material adverse effect. Additionally, a dispute regarding the sale of Trukke Winter Sports Products was settled in April 1999.
- Regulatory Risks: The European Commission has imposed 49.2% anti-dumping duties on footwear from China/Indonesia. Dutch Customs indicated certain Teva styles may be covered, creating a potential exposure of up to $500,000 in prior duties and risking future import costs.
- License Expiration: The Teva license expires August 31, 2001. The Company is negotiating renewal or purchase of rights. Failure to secure a favorable arrangement would materially impact operations.
- Year 2000 Compliance: The Company is in the testing phase for enterprise systems, with completion expected by June 30, 1999. Estimated compliance costs are approximately $350,000 for enterprise systems plus additional costs for other IT/non-IT systems.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with the tangible net worth covenant ($30M minimum) under the new $50M credit facility.
- Receivables Quality: Monitor the $45M accounts receivable balance and the $1.5M allowance for doubtful accounts, given the noted deterioration in average collection periods.
- Legal Exposure: Track the status of the Montana lawsuit appeal and the Dutch Customs anti-dumping determination.
- License Renewal: Assess progress on negotiations with Mark Thatcher regarding the Teva license extension beyond 2001.
- Seasonality Impact: Confirm Q2 sales performance to ensure the Q1 "pull-forward" strategy does not result in a significant Q2 revenue shortfall.